The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy

Arquivos de Gastroenterologia

Volumn 40, Issue 1, 2003, Pages 55-60

  Eisig, Jaime Natan ^a,b   Boaventura André, Suraia ^a   Silva, Fernando Marcuz ^a   Hashimoto, Cláudio ^a   Pinto Moraes Filho, Joaquim Prado ^a   Laudanna, Antonio Atilio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Anti ulcer agents; Benzimidazoles; Helicobacter infections; Helicobacter pylori; Peptic ulcer; Sulfoxides

Indexed keywords

CLARITHROMYCIN; METRONIDAZOLE; NITROIMIDAZOLE; PANTOPRAZOLE; UREASE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; DUODENUM ULCER; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HYPERSALIVATION; MALE; NAUSEA; PILOT STUDY; SHORT COURSE THERAPY; SIDE EFFECT; STOMACH BIOPSY; TASTE DISORDER; TREATMENT OUTCOME;

EID: 0345305824     PISSN: 00042803     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0004-28032003000100012     Document Type: Article

References (32)

1. Adamek JR, Bethke TD and the International Pantoprazole HP Study Group. Cure of H. pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two week dual therapy. Am J Gastroenterol 1998;93:1919-24.
2. Bazzoli F, Zagari MR, Fossi S. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6:773-7.
3. Bell GD, Powell KU, Burridge SM, Spencer G, Boltan G, Pursar K, Brooks S, Prosser S. Experience with triple anti-Helicobacter pylori eradication therapy: side-effects and the importance of testing the pre-treatment bacterial isolate for metronidazol resistance. Aliment Pharmacol Ther 1992;4:427-35.
4. Chehter EZ, Silva FM, Eisig JN, Silva JJ, Laudanna AA. H. pylori eradication: high efficacy week treatment with clarithromycin 500 mg bid, amoxicilin 1,0 gr bid plus lansoprazole 30 mg bid in São Paulo, Brazil. Am J Gastroenterol 1999,94:A118.
5. Chiba N. Low dose omeprazole + clarithromycin + metronidazole in the eradication of Helicobacter pylori: interim results [abstract]. Am J Gastroenterol 1994;94:A1367.
6. Dammann HG, Folsch UR, Hahn EG, von Kleist DH, Klor HV, Kirchner T, Strobel S, Kist M. Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. Helicobacter 2000;5:41-51.
7. Ellenrieder V, Boeck W, Richter C, Marre R, Adler G, Glasbrenner B. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand J Gastroenterol 1999;34:750-6.
8. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997;41:8-13.
9. Goddard A, Logan R. One-week low-dose triple therapy: new standards for Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1995;7:1-3.
10. Houben MH, Van Der Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047-55.
11. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther 1999;13:719-29.
12. Hunt RH, Malfertheiner P, Yeomans ND, Hawkey CJ, Howden CW. Critical issues in the pathophysiology and management of peptic ulcer disease. Meeting report. Eur J Gastroenterol Hepatol 1995;7:685-99.
13. Jaup BH, Norrby A. Low dose, short-term triple therapy for cure of Helicobacter pylori and healing of peptic ulcers. Am J Gastroenterol 1995;90:943-5.
14. Labenz J, Peitz U, Tillenburg B, Becker T, Borsch G, Stolte M. Short-term triple therapy with pantoprazole, clarithromycin and metronidazole nietronidazole for eradication of Helicobacter pylori. Leber Magen Darm 1995;25:122-7.
15. Labenz J, Stolte M, Ruhl HG, Becker T, Tillenburg B, Sollbohmer M, Borsch G. One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995;7:9-11.
16. Lind T, Veldhuyzen van ZS, Unge P, Spiller R, Bayerdorffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C, Idstrom JP. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1996;1:138-44.
17. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol 1993;28(suppl 196):34-7.
18. Mégraud F. H. pylori resistance to antibiotics. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori - Basic mechanism to clinical cure. Dordrecht: Kluwer; 1994. p.570-83.
19. Mégraud F. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999;43:2747-52.
20. Mendonça S, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, Pedrazzoli J. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter 2000;5:79-83.
21. Midolo PD, Bell JM, Lambert JR, Turnidge JD, Grayson ML. Antimicrobial resistance testing of Helicobacter pylori: a comparison of E-test and disk diffusion methods. Pathology 1997;29:411-4.
22. Misiewicz JJ, Harris AW, Bardhan KD, Levi S, O'Morain C, Cooper BT, Kerr GD, Dixon MF, Langworthy H, Piper D. One-week triple therapy for Helicobacter pylori: a multicenter comparative study. Lansoprazole Helicobacter Study Group. Gut 1997;41:735-9.
23. Moayyedi P, Tompkins DS, Ragunathan PL. Relevance of metronidazole resistance in predicting failure of omeprazole, clarithromycin and tinidazole to eradicate Helicobacter pylori. Gut 1996;39(Suppl.2):A6.
24. Modlin IM, Sachs G. Helicobacter pylori. Infection and its consequences. In: Modlin IM, Sachs G. Acid related diseases. Biology and treatment. New Haven: Schneitzor Verlag; 1998. p.345-62.
25. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994;272:65-9.
26. Peterson WL, Graham DY, Marshall B, Blaser MJ, Genta RM, Klein PD, Stratton CW, Drnec J, Prokocimer P, Siepman N. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double blind trial. Am J Gastroenterol 1993;88:1860-4.
27. Queiroz DM, Coimbra RS, Mendes EN, Rocha GA, Alves VM, Oliveira CA, Lima Jr GF. Metronidazol resistant Helicobacter pylori in a developing country. Am J Gastroenterol 1993,88:322-3.
28. Teare JP, Booth JCL, Brown JL, Martin J, Thomas HC. Pseudomembranous colitis following clarithromycin therapy. Eur J Gastroenterol Hepatol 1995;7:275-7.
29. Tompkins DS, Perkin J, Smith C. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 1997;2:185-7.
30. Xia H, Keane CT, Beattie S, O'Morain CA. Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob Agents Chemother 1994;38:2357-61.
31. Xia HX, Buckley M, Hyde D. Effects of antibiotic resistance on clarithromycin-combined triple therapy for Helicobacter pylori [abstract]. Gut 1995:37(Suppl 1):A55.
32. Yousfi MM, el-Zimaity HM, al-Assi MT, Cole RA, Genta RM, Graham DY. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9:209-12.